Uther Pharmaceuticals is owned by a group of talented scientists from Xi'an Company, with comprehensive capabilities in the development of cloned cells, upstream and downstream processes, and analytical research.
Products based on recombinant proteins and mAb are focused on developing treatment products for important diseases such as autoimmune diseases, assisted reproductive therapy, and infertility treatment.
Products based on recombinant proteins and mAb are focused on developing treatment products for important diseases such as autoimmune diseases, assisted reproductive therapy, and infertility treatment.
The human drug discovery work aims to identify and develop new therapies for diseases including metabolic disorders, liver, and autoimmune diseases. Uther's focus and clear strategy enable us to identify promising candidates, and we are building strong molecular pipelines for our preclinical and clinical development. This stable exercise will ensure that at least one compound enters the clinical stage for the first human study every year. The New Drug Discovery and Research (NDDR) department has the ability to conduct drug discovery and development from concept to IND, enabling preclinical and clinical research
Type 2 diabetes
Type 2 diabetes (T2DM) is characterized by insulin resistance and β Chronic diseases characterized by cell failure, whose potential genetic susceptibility is severely influenced by diet and lifestyle. The discovery of NDDR focuses on the goal of providing continuous blood sugar control, with a focus on reducing insulin resistance and protection β Cell function.
Indicating Hit Leading Clue
Optimize candidates
Select IND Phase 1, Phase 2, Phase 3
T2DM
T2DM
hepatopathy
Non alcoholic steatohepatitis (NASH) originates from the stable accumulation of fat in the liver, which can cause inflammation and ultimately lead to scarring and cirrhosis. Mankind's research focuses on patients with advanced fibrosis caused by NASH.
Indicating Hit Leading Clue
Optimize candidates
Select IND Phase 1, Phase 2, Phase 3
Non alcoholic steatohepatitis
Anti-inflammatory
When a person's immune system is unable to distinguish between normal and unhealthy cells, autoimmune diseases occur, leading to the immune system attacking healthy organs and tissues in the body. In humans, our goal is to find new therapies that may have potential therapeutic effects on inflammatory diseases.
Indicating Hit Leading Clue
Optimize candidates
Select IND Phase 1, Phase 2, Phase 3
Autoimmune disorders